Jan 21 (Reuters) - Atara Biotherapeutics Inc ATRA.O:
ATARA BIOTHERAPEUTICS PROVIDES UPDATE ON CLINICAL PROGRAMS RELATED TO EBVALLO™ (TABELECLEUCEL) AND ATA3219
ATARA BIOTHERAPEUTICS INC: FDA HAS PLACED A CLINICAL HOLD ON ATARA'S ACTIVE INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS
ATARA BIOTHERAPEUTICS INC: FDA ISSUES CLINICAL HOLD ON EBVALLO™ (TABELECLEUCEL) AND ATA3219 STUDIES LINKED TO EBVALLO COMPLETE RESPONSE LETTER
ATARA BIOTHERAPEUTICS INC: SCREENING AND ENROLLMENT OF NEW PARTICIPANTS IN BOTH PROGRAMS HAVE BEEN PAUSED
Source text: ID:nBw99pdYma
Further company coverage: ATRA.O